Fintel reports that on January 15, 2025, Wells Fargo upgraded their outlook for CareDx (NasdaqGM:CDNA) from Underweight to Equal-Weight.
Analyst Price Forecast Suggests 55.96% Upside
As of December 24, 2024, the average one-year price target for CareDx is $34.39/share. The forecasts range from a low of $28.28 to a high of $42.00. The average price target represents an increase of 55.96% from its latest reported closing price of $22.05 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for CareDx is 418MM, an increase of 33.66%. The projected annual non-GAAP EPS is 0.07.
What is the Fund Sentiment?
There are 490 funds or institutions reporting positions in CareDx. This is an increase of 116 owner(s) or 31.02% in the last quarter. Average portfolio weight of all funds dedicated to CDNA is 0.28%, an increase of 44.61%. Total shares owned by institutions increased in the last three months by 0.31% to 65,919K shares. 
The put/call ratio of CDNA is 0.19, indicating a bullish outlook.
What are Other Shareholders Doing?
Bellevue Group holds 3,145K shares representing 5.86% ownership of the company. In its prior filing, the firm reported owning 3,913K shares , representing a decrease of 24.39%. The firm increased its portfolio allocation in CDNA by 61.16% over the last quarter.
ARK Investment Management holds 2,989K shares representing 5.57% ownership of the company. In its prior filing, the firm reported owning 5,702K shares , representing a decrease of 90.80%. The firm increased its portfolio allocation in CDNA by 8.61% over the last quarter.
ARKG - ARK Genomic Revolution ETF holds 2,696K shares representing 5.03% ownership of the company. In its prior filing, the firm reported owning 4,870K shares , representing a decrease of 80.59%. The firm decreased its portfolio allocation in CDNA by 23.89% over the last quarter.
Bamco holds 1,877K shares representing 3.50% ownership of the company. No change in the last quarter.
Sumitomo Mitsui Trust Holdings holds 1,654K shares representing 3.08% ownership of the company. In its prior filing, the firm reported owning 2,576K shares , representing a decrease of 55.77%. The firm increased its portfolio allocation in CDNA by 21.19% over the last quarter.
Caredx Background Information
(This description is provided by the company.)
CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
